Bladder Cancer, Invasive Bladder Cancer, Metastatic Bladder Cancer
Conditions
Keywords
muscle invasive bladder cancer, non-muscle invasive bladder cancer, radical cystectomy, monoclonal antibodies, Avelumab, Invasive Resectable disease, MIBC, NMIBC, neoadjuvant chemotherapy
Brief summary
This is a pilot study of avelumab in patients with non-metastatic, muscle invasive bladder cancer who are eligible for radical cystectomy (RC), but are ineligible for cisplatin based neoadjuvant therapy. The target recruitment is 10 evaluable patients for this window of opportunity study. Pre- and post-treatment tumor samples from transurethral resection of the bladder tumor and RC will be used for study endpoints.
Detailed description
Avelumab is a fully human monoclonal PD-L1 antibody of the immunoglobulin G1 (IgG1) subclass. It works by binding to PD-L1 on tumor cells, immune cells and/or stromal cells. This prevents PD-L1 from interacting with PD-1. Inhibition of this interaction increases activation/survival of antitumor lymphocytes. It also increases innate immunity by resulting in decreased PD-1 suppression of NK cell function and bolsters antibody production by B cells due to less PD-L1 binding of PD-1 on B-cells. Additionally, avelumab has been suggested to have another mechanism involving antibody dependent cellular cytotoxicity (ADCC). ADCC in these cases involves NK cell recognition and lysis of tumor cells that have antibody bound to PD-L1. By blocking PD-L1, avelumab leads to less CD80 binding by PD-L1 and more CD80-CD28 binding in response to antigen presentation to T-cells. This results in increased costimulatory signaling and is another mechanism by which avelumab may enhance T-cell activation. Avelumab has been shown to be efficacious across multiple metastatic tumor types, including urothelial cancer. The phase Ib study has reported survival and safety outcomes with \>12 months followup using pooled data on 249 patients with metastatic UC (Apolo et al, ESMO Sept 2017). Patients had been treated with a median of 2 prior therapies in the metastatic setting and 13 patients who were cisplatin-ineligible were evaluated for safety alone. PD-L1 expression was not a criterion for enrollment. The confirmed objective response rate (ORR) was 16.1%, with 5% complete responses and 11.2% partial responses. The 6-month progression-free survival was 27%. The ORR was better than or comparable to chemotherapy in historical controls. Among responders, 70.3% were maintained \> 12 months. Treatment-related adverse events (AE) occurred in 70%, with 10.7% of the total with AE's of grade \>3. Immune-mediated AE's occurred in 18.5%, of which 4% were grade \>3. There is currently a phase III clinical trial ongoing comparing avelumab to standard of care chemotherapy in the second line setting or beyond for metastatic UC. Two other checkpoint inhibitors have been approved in the last 2 years for first line treatment of patients with metastatic UC who are ineligible for cisplatin-based therapy.
Interventions
DRUGAvelumab
avelumab 10 mg/kg intravenously every 2 weeks for 3 cycles or 42 days.
Sponsors
Pfizer
Baylor College of Medicine
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Have undergone TURBT showing newly diagnosed muscle invasive UCB (mixed histology is allowed if the predominant histology is UCC) within 6 weeks prior to cycle 1, day 1 of treatment. * No prior systemic treatment for muscle invasive UCB * Clinical T2-T4a disease * No evidence of clinically positive lymph nodes or distant metastasis on computed tomography (CT) scans of chest and CT or magnetic resonance imaging (MRI) studies of the abdomen/pelvis. Imaging must be within 90 days of registration. * Male or female subjects aged ≥ 18 years old. * Must have adequate kidney, liver, and bone marrow function within 30 days of registration, as follows: * Absolute neutrophil count (ANC) ≥ 1.5 × 109/L * platelet count ≥ 100 × 109/L * hemoglobin ≥ 9 g/dL (may have been transfused) * Total bilirubin level ≤ 1.5 × ULN * AST and ALT levels ≤ 2.5 × ULN * Estimated creatinine clearance ≥ 30 mL/min according to the Cockcroft-Gault formula * Negative serum or urine pregnancy test at screening for women of childbearing potential (WOCBP), within 30 days of registration. * Both male and female subjects must agree to use highly effective contraception (see Section 6.1 Table 8) while receiving avelumab and for at least 60 days after last avelumab treatment if the risk of conception exists. Female patients must agree to inform study coordinator or investigator immediately if they think they have become pregnant during the study. * Must have FFPE tissue available from the TURBT, and patient must consent to the use of tissue specimens from TURBT and RC for the study. * Patients must be ineligible for cisplatin-based NAC. Ineligibility criteria include: creatinine clearance \< 60 ml/min by Cockcroft-Gault formula, CTCAE grade ≥ 2 hearing loss, CTCAE grade ≥ 2 neuropathy, and at discretion of medical oncologist. * Must be eligible for RC in the opinion of the treating investigator, and willing to undergo this procedure. * ECOG performance status (PS) score of 0-2 * Signed informed consent form.
Exclusion criteria
Patients must not have any of the following: * IMMUNOSUPRESSANTS: Current use of immunosuppressive medication or within 4 weeks of C1D1, EXCEPT for the following: a. intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); b. Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent; c. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication). * AUTOIMMUNE DISEASE: Active autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent. Patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment are eligible. Patients with type I diabetes or hypo- or hyperthyroidism should be on stable doses of medications for participation. * ORGAN TRANSPLANTATION: Prior organ transplantation including allogenic stem-cell transplantation. * INFECTIONS: Active infection requiring systemic therapy. * HIV/AIDS: Known history of testing positive for HIV or known acquired immunodeficiency syndrome. * HEPATITIS: Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening test positive) * VACCINATION: Vaccinate within 4 weeks of the first dose of avelumab and while on study drug is prohibited except for administration of inactivated vaccines * HYPERSENSITIIVTY TO STUDY DRUG: Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v4.03 Grade ≥ 3) * CARDIOVASCULAR DISEASE: Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (\< 6 months prior to enrollment), myocardial infarction (\< 6 months prior to enrollment), unstable angina, congestive heart failure (≥ New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication. * Other severe acute or chronic medical conditions including colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study. * Relapsed MIBC (all patients participating in the study should be newly diagnosed) * Concomitant UCC outside the bladder (e.g., ureter, urethra or renal pelvis) * Underlying immune disorder (e.g., combined variable immunodeficiency syndrome) * Erythropoietin receptor agonists within 30 days prior to enrollment. * G-CSF, GM-CSF or TPO mimetics during the study period or within 3 weeks prior to study enrollment * Malignancies other than UCB within 5 years prior to Cycle 1, Day 1, with the exception of those with low risk of metastasis or death treated with expected curative outcome (such as, but not limited to, adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated with curative intent and absence of PSA relapse, or ductal carcinoma in situ of the breast treated surgically with curative intent) or incidental prostate cancer (T1a, Gleason score ≤ 6 and PSA \< 0.5 ng/ml) * Prior immunotherapy with T-cell co-stimulation or checkpoint targeted agents (e.g., CTLA-4 inhibitors, anti-PD1 antibodies or anti-PD-L1 antibodies) * Intravesical chemotherapy or biologic therapy within 6 weeks of Cycle 1, Day 1 * Current participation in another clinical trial for MIBC * Nursing or pregnant woman * Uncontrolled cystitis, significant bladder pain or spasms, or gross hematuria that in the opinion of the principal investigator will preclude study participation * Major surgical procedures within 4 weeks of registration (other than for diagnosis) or anticipation that such a procedure will be needed during the study (other than RC)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in T Cell Subpopulations | pre-study time and 2-3 week post-operation | The change in T cell subpopulations (CD8, CD4 and/or CD3) in tumor samples will be collected from FFPE tissue. FFPE tissue from the pre-study time point refers to tissue from the TURBT. FFPE tissue from the 2-3 week post-op time point refers to FFPE tissue from the RC |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pathological Response Rate | pre-study time and 2-3 week post-operation | Number of patient with pathological response will be counted |
| 2 Year Disease Free Survival (DFS) | 2 years after radical cystectomy | A patient will be followed for recurrence and survival for up to 2 years after radical cystectomy. |
| Rate of High Grade(Grade 3-4) Adverse Event | 90 days post operation | High grade adverse events are defined as grade of 3-4 on the CTCAE (Common terminology criteria for adverse events) grading scale. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Avelumab Avelumab 10 mg/kg intravenously, over 60 minutes every 2 weeks for 3 cycles or 42 days.
Avelumab: avelumab 10 mg/kg intravenously every 2 weeks for 3 cycles or 42 days. | 1 |
| Total | 1 |
Baseline characteristics
| Characteristic | Avelumab |
|---|---|
| Age, Continuous | 58 years |
| Current Smoking | 1 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 1 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 0 Participants |
| Region of Enrollment United States | 1 participants |
| Sex: Female, Male Female | 0 Participants |
| Sex: Female, Male Male | 1 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 1 / 1 |
| other Total, other adverse events | 1 / 1 |
| serious Total, serious adverse events | 1 / 1 |
Outcome results
Primary
Change in T Cell Subpopulations
The change in T cell subpopulations (CD8, CD4 and/or CD3) in tumor samples will be collected from FFPE tissue. FFPE tissue from the pre-study time point refers to tissue from the TURBT. FFPE tissue from the 2-3 week post-op time point refers to FFPE tissue from the RC
Time frame: pre-study time and 2-3 week post-operation
Population: The assay for the outcome measure was planned to do after enrolling several patients and collecting specimen but only one patient was enrolled for this study. No assay was done.
Secondary
2 Year Disease Free Survival (DFS)
A patient will be followed for recurrence and survival for up to 2 years after radical cystectomy.
Time frame: 2 years after radical cystectomy
Population: since one patient was available for this study analysis, the time of recurrence or death was reported.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Avelumab | 2 Year Disease Free Survival (DFS) | 5.48 months |
Secondary
Pathological Response Rate
Number of patient with pathological response will be counted
Time frame: pre-study time and 2-3 week post-operation
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Avelumab | Pathological Response Rate | 0 Participants |
Secondary
Rate of High Grade(Grade 3-4) Adverse Event
High grade adverse events are defined as grade of 3-4 on the CTCAE (Common terminology criteria for adverse events) grading scale.
Time frame: 90 days post operation
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Avelumab | Rate of High Grade(Grade 3-4) Adverse Event | 1 Participants |